Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WZTL 002

Next Previous
Drug Profile

WZTL 002

Alternative Names: Anti-CD19 CAR T-cells - Wellington Zhaotai Therapies; Anti-CD19 chimeric antigen receptor T cell therapy - Wellington Zhaotai Therapies; Autologous 1928T2z CAR-T cells; WZTL-002; WZTL002-1

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wellington Zhaotai Therapies
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Feb 2025 Updated efficacy, adverse events and pharmacokinetics data from the phase I ENABLE-1 trial in Non-Hodgkin’s lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 30 Jun 2024 Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies plans the phase II ENABLE-2 trial for B-cell Lymphoma and Non-Hodgkin Lymphoma (Second-line therapy or greater) in New Zealand (IV) (NCT06486051)
  • 19 Jan 2024 Phase-I development in Non-Hodgkin's-lymphoma (In adolescents, In the elderly, Second-line therapy or greater, In adults) is still ongoing in New Zealand (IV, Infusion) (NCT04049513)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top